[go: up one dir, main page]

WO2023059809A3 - Methods and agents for prevention of viral proliferation - Google Patents

Methods and agents for prevention of viral proliferation Download PDF

Info

Publication number
WO2023059809A3
WO2023059809A3 PCT/US2022/045913 US2022045913W WO2023059809A3 WO 2023059809 A3 WO2023059809 A3 WO 2023059809A3 US 2022045913 W US2022045913 W US 2022045913W WO 2023059809 A3 WO2023059809 A3 WO 2023059809A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
nps
viruses
viral
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/045913
Other languages
French (fr)
Other versions
WO2023059809A2 (en
Inventor
Mark Grinstaff
Brett TINGLEY
Anton PETCHERSKI
Aaron COLBY
Orian S. SHIRIHAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Boston University
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, University of California Berkeley, University of California San Diego UCSD filed Critical Boston University
Publication of WO2023059809A2 publication Critical patent/WO2023059809A2/en
Publication of WO2023059809A3 publication Critical patent/WO2023059809A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In various embodiments, novel biodegradable solid lipid nanoparticles (SLNs) and poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18) nanoparticles are used to deliver palmitic acid and/or antivirals to stunt viral replication. These nanoparticles (NPs) rapidly localize to lysosomes where they are degraded and release component fatty acids that increase lysosomal pH, thereby decrease the ability of pH-dependent proteases to cleave viral proteins that initiates viral genome release into the cell cytosol. These NPs serve as a therapeutic to reduce proliferation of viruses reliant upon the endocytic pathway for infection, e.g., respiratory viruses such as coronaviruses, influenza A and respiratory syncytial virus.
PCT/US2022/045913 2021-10-06 2022-10-06 Methods and agents for prevention of viral proliferation Ceased WO2023059809A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252763P 2021-10-06 2021-10-06
US63/252,763 2021-10-06

Publications (2)

Publication Number Publication Date
WO2023059809A2 WO2023059809A2 (en) 2023-04-13
WO2023059809A3 true WO2023059809A3 (en) 2023-05-11

Family

ID=85803714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/045913 Ceased WO2023059809A2 (en) 2021-10-06 2022-10-06 Methods and agents for prevention of viral proliferation

Country Status (1)

Country Link
WO (1) WO2023059809A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311214A1 (en) * 2006-04-05 2008-12-18 Transgene Biotek Limited Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
US20140235706A1 (en) * 2007-09-28 2014-08-21 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311214A1 (en) * 2006-04-05 2008-12-18 Transgene Biotek Limited Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
US20140235706A1 (en) * 2007-09-28 2014-08-21 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JESSE B. WOLINSKY, STEFAN T. YOHE, YOLONDA L. COLSON, MARK W. GRINSTAFF: "Functionalized Hydrophobic Poly(glycerol- co -ε-caprolactone) Depots for Controlled Drug Release", BIOMACROMOLECULES, AMERICAN CHEMICAL SOCIETY, US, vol. 13, no. 2, 13 February 2012 (2012-02-13), US , pages 406 - 411, XP055240514, ISSN: 1525-7797, DOI: 10.1021/bm201443m *
TAN JIA YING BRENDA, YOON BO KYEONG, CHO NAM-JOON, LOVRIĆ JASMINA, JUG MARIO, JACKMAN JOSHUA A.: "Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 18, pages 9664, XP093065716, DOI: 10.3390/ijms22189664 *

Also Published As

Publication number Publication date
WO2023059809A2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CY1123945T1 (en) IMMEDIATE RELEASE ORAL FORMULATIONS FOR SUBSTITUTED QUINAZOLINONES
Chen et al. Novel technology for the preparation of self-assembled catechin/gelatin nanoparticles and their characterization
CO6700848A2 (en) Enteric coated pancreliplase formulations, low intensity
WO2008058547A3 (en) Alpha-lactalbumin composition
MXPA05012821A (en) Pharmaceutical formulation comprising a water-insoluble active agent.
Sgarbanti et al. Intracellular redox state as target for anti-influenza therapy: are antioxidants always effective?
HRP20200925T1 (en) PREPARATION FOR THE TREATMENT OF DIABETES INCLUDING AN OXINTOMODULIN ANALOG
CO6531471A2 (en) ACID RESISTANT CAPSULES
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
WO2009100181A3 (en) Absorbent ingestible agents and associated methods of manufacture and use
CY1119216T1 (en) PHARMACEUTICAL COMPOSITION FOR INHALATION
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
MX2009012782A (en) Formulations for the oral administration of therapeutic agents and related methods.
IL303225A (en) Reducing viral infections
CA2905449C (en) THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
Iyer et al. Bioengineering strategies for developing vaccines against respiratory viral diseases
EE200200504A (en) Pharmaceutical preparations
Sinani et al. Applications of chitosan in prevention and treatment strategies of infectious diseases
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2023059809A3 (en) Methods and agents for prevention of viral proliferation
MX346316B (en) Pharmaceutical or neutraceutical formulation.
ECSP034915A (en) PHARMACEUTICAL FORMULATION OF MASKED FLAVOR AND PROCEDURE FOR PREPARATION
CN115697354B (en) Compositions and methods for treating SARS-COV-2 infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22879294

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22879294

Country of ref document: EP

Kind code of ref document: A2